Introduction
The c-jun N-terminal kinases (JNKs) are serine/threonine protein kinases and belong to an important family of mitogen-activated protein kinases. 1 JNK is activated in response to stress challenges, and is critical in the development of cancers, diabetes, and cardiovascular diseases (CVDs; e.g. myocardial infarction, atherosclerosis, heart failure). [1] [2] [3] [4] [5] role in the development of atrial fibrillation (AF), the most common arrhythmia in the aging population. [8] [9] [10] Although aging is a major risk factor for AF development, there are no clear age-related cell signalling pathways known to promote the association between age and AF. Accumulating studies suggest a crucial role of CaMKII in calcium (Ca 2þ ) mishandling triggered AF. [11] [12] [13] [14] CaMKIId is a well-known cardiac pro-arrhythmic molecule that phosphorylates Ca 2þ handling proteins including phospholamban, Ca 2þ releasing ryanodine receptors (RyRs), inositol 1, 4, 5-trisphosphate receptors (IP 3 R), and L-type Ca 2þ channels, thereby playing a crucial role in the excitation-contraction coupling in the normal heart and enhanced arrhythmogenicity in the pathologically remodelled heart. [15] [16] [17] [18] [19] Thus, CaMKIId inhibition has been considered as a potential anti-arrhythmic intervention. [20] [21] [22] However the outcomes have not been as optimal as expected due to some off-target effects. 23 Understanding how CaMKIId expression is regulated will greatly aid in developing novel anti-arrhythmic drugs to inhibit CaMKIId.
Here we discovered that JNK activation is concurrently linked to significantly increased CaMKIId expression in the human atrium with increasing age. We further demonstrated that this JNK enhanced CaMKIId expression is a JNK2 isoform-specific action. By using silico analysis and a unique cross-linked chromatin-immunoprecipitation (XChIP) assay, we revealed for the first time that JNK downstream transcription factors c-jun and activating transcription factor2 (ATF2) are bound to the CaMKIId proximal promoter region. We further discovered that increased binding of cjun to the CaMKII promoter leads to elevated promoter activity by using either JNK ablation or c-jun knockdown. Our findings reveal a previously unrecognized molecular mechanism of JNK2 regulated CaMKIId expression that underlies the pathogenesis of atrial arrhythmias in the elderly. Our results provide an important basis for modulating JNK2 activity as a potential novel therapeutic approach for AF.
Methods

Human atrial specimens
Human atrial tissues were obtained from 11 human donor hearts provided by Illinois Gift of Hope Organ and Tissue Donor Network (GOH). These hearts were not used for heart transplantation but had no history of AF and/or major CVDs. Table 1 shows de-identified data (age, gender, race, etc.) from the donors. The studies were approved by the Human Study Committees of Loyola University Chicago, Rush University Medical Center, and Illinois GOH. Consent was obtained by GOH from the donors' families for use of donor hearts for research. These human heart studies were performed to conform to the Declaration of Helsinki.
Animal preparations
Wild-type (WT) C57B/6j mice (Jackson Laboratory, ME) at 26 months (aged) and 2-2.5 months (young) were studied. To assess the functional action of JNK on CaMKIId expression, we used 2-month old cardiac-specific inducible MKK7D (aMHC-cre) young transgenic mice (a generous gift from Dr. Yibin Wang, UCLA) that express cardiac-specific MKK7D to robustly activate JNK with tamoxifen treatment (50 mg/kg I.P. for 5 constitutive days. 7, 24 Mice were studied five days after the last dose of tamoxifen treatment. Mice were sedated via isoflurane inhalation (2% isoflurane delivered in 100% oxygen) and cardiac function was assessed using echocardiography. Left ventricular (LV) dimensions (from both short axis view and long axis four-chamber view) of mouse hearts were assessed using 2D echocardiography (vevo2100) as described previously in. 6, 15 Ejection fraction (EF) and fractional shortening (FS) were analysed as previously described. 6, 15 In addition, aged WT mice were treated in vivo with a JNK2 inhibitor JNK2I-IX 25 (10 mg/kg, I.P. every other day for a total of 10 days). Mice were sacrificed under a surgical plane of anaesthesia induced with a mixture of 100 mg/kg ketamine and 4.5 mg/kg Xylazine (I.P.) for terminal studies. All animal studies followed the Guide for the Care and Use of Laboratory Animals (NIH Publication, 8th Edition, 2011) and were approved by the Institutional Animal Care and Use Committees of Loyola University Chicago.
Reagents and antibodies
JNK activator anisomycin and JNK-specific inhibitors SP600125 and JNK2I-IX were used as previously described. 6, 25, 26 Antibodies recognizing JNK1, JNK2, phosphorylated total JNK (JNK-P) (Cell Signalling) and CaMKIId (Abcam) were used for immunoblotting assays. The antibodies against c-jun or ATF2 used for XChIP were from Cell Signalling and Abcam, respectively.
Plasmid construction
The sequence 1.2 kb upstream of the mouse CaMKIId transcriptional start codon was amplified by using PCR from a mouse genomic clone with primers harbouring KpnI and BglII sites and inserted into the luciferase reporter vector pGL3 at the corresponding restriction sites. The inserted sequences were verified by sequencing.
Culture and treatment of HL-1 myocytes
Mouse HL-1 myocytes were kindly provided by Dr William Claycomb (Louisiana State University) and cells were strictly maintained and passaged as previously described. 6, 27 On the fourth day after cell plating, 
Western blotting
The heart tissues from humans and mice were homogenized in RIPA buffer. Mouse atrial HL-1 cells were also lysed in RIPA. After clearing by centrifugation, lysates (20 mg) were subjected to Western blotting using specific antibodies. The proteins were visualized with ECL reagent (Thermo Scientific) and scanned with a Bio-Rad gel imaging system. The protein levels were quantified with the gel imager software and normalized with internal loading control glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
RNA preparation and quantitative real time PCR
Total RNA was extracted with Trizol reagent (Thermo Fisher Scientific).
The quantity and quality of the prepared RNA were determined by UV spectrometry. An aliquot of RNA (1 mg) was reverse-transcripted to cDNA. The amounts of mRNA were then detected by qPCR with specific primers and GoTaq SYBR Master Mix (Promega) using the CFX96 real-time PCR detection system (Bio-Rad), and normalized with GAPDH. The sequences of CaMKIId primers used for real time PCR were: Forward: GGCAGACTTCGGCTTAGCCATAG; Reverse: TCATCCCAGAAGGGTGGGTACC
Cross-link chromatin immunoprecipitation
The experiment was started 24 h after treatment of HL-1 cells with anisomycin as previously described in. 6, 7 In brief, cells were cross-linked with 1% formaldehyde for 10 min at room temperature, followed by 5 min incubation with 0.125 mol/l glycine. The cells were lysed in a SDS lysis buffer containing protease inhibitors (Sigma-Aldrich) followed by sonication. The supernatant of the cell lysates was incubated with 0.5 mg anti-c-jun antibody (Cell Signalling), 1 mg/ml anti-ATF2 antibody (Abcam) or rabbit IgG, respectively, and immunoprecipitated (IP-ed) with 20 ml protein A/G conjugated magnetic beads (EMD). The elutes containing bound DNAs from the c-jun or ATF2 immunoprecipitates were concentrated to 200 mmol/l with NaCl and incubated at 62 C for 2 h, then subjected to 95 C for 10 min. After purification, the IP-ed DNA was quantified by real-time PCR using the primers flanking the potential AP-1 binding site in the mouse CaMKIId proximal promoter region (sequences of primers, forward: CAGGCTAGGCACGCTCACGTGAC, reverse: GGGCGGTAGG AAGGTTGGCT) and the SYBR master mix (Promega). The quantitative amounts of DNA were normalized to the total input and presented as enrichment.
Promoter activity assay
Plasmid pGL3-CaMKIId-WT or CaMKIId-mu that contain either an inserted WT or mutated (replaced -716 T/-715 G to A/C) mouse CaMKIId promoter sequence upstream from the encoded Firefly luciferase were transfected into HEK293 cells together with a reference plasmid pTK-RL, which constitutively expresses Firefly luciferase. The following day, cells were incubated with anisomycin at 50 ng/ml for 24 h. Luciferase activity assay was measured by Pherastar (BMG LABTECH) using the Dual-Luciferase Reporter System (Promega) following the manufacturer's instructions. The results were normalized with Renilla luciferase activity to correct the variation in transfection efficiency.
In vitro JNK activity assay
Mouse heart tissue was homogenized in a lysis buffer (mM: TrisHCl 40, NaCl 150, ß-glycerophosphate 5, NaF 10, Na 3 VO 4 0.2, and protease inhibitor cocktail, pH 7.4). Lysates were incubated with 1 mg/ml anti-JNK1 or JNK2 antibody (Abcam) and 7.5 ml of protein G beads followed by kinase activity assay. In brief, the resultant IP was resuspended in the kinase reaction buffer in the presence of 20 mM ATP and 1 mg c-jun, and incubated at room temperature for 45 min. At the end of the reaction, the kinase activity detection was conducted using the ADP-Glo Kinase Assay Kit (Promega) following the manufacturer's instructions. The results are presented as relative light units.
Statistical analysis
All data are presented as means ± SEM. Differences between two groups were evaluated using One-Way ANOVA with Tukey post hoc test and P < 0.05 was considered to be significant.
Results
JNK activation is linked to a significantly increased CaMKIId protein level in human atria with increasing age
We assessed protein expression of CaMKIId in human atria that were obtained from donors with a normal cardiac function and no history of AF or major CVDs ( Table 1) . Quantitative immunoblotting assays showed that increased CaMKIId protein was positively correlated with elevated JNK-P (activated JNK) in the human atrium with increasing age ( Figure 1A and B). In contrast, levels of JNK1 and JNK2 proteins were not different between the human atrial samples with increasing age ( Figure 1C) . This concurrent increase of JNK-P and CaMKIId in the aged human atria led us to investigate the functional role of JNK activation on CaMKIId expression. To measure the JNK specific action in CaMKIId
expression without interfering with other potential confounding factors in the aged heart, cardiac specific tamoxifen-inducible MKK7D mice were studied. 24 Induction of constitutively activated MKK7, an upstream activator of JNK, led to significant activation of JNK ( Figure 2A) . Previous studies have suggested that long-term MKK7 activation (2-months posttamoxifen induction) leads to an impaired cardiac function. 24 However, MKK7D Tg mice (MKK7D þ -Tx) with a short-term post-tamoxifen induction (5 days) showed significantly activated JNK but a comparable ventricular EF and FS to that of tamoxifen-treated WT littermates (MKK7D --Tx; Figure 2B ). As shown in Figure 2C , CaMKIId was markedly increased in JNK activated MKK7D þ mice, suggesting JNK activation contributes to enhanced CaMKIId expression.
JNK2 isoform specific action in CaMKIId protein expression in aged mice
JNK1 and JNK2 are the two major isoforms expressed in myocytes and the two isoforms were found to have distinctive functions.
2,28,29
Therefore, we assessed JNK isoform-specific action in CaMKIId expression. JNK1 and JNK2 proteins in the aged mouse heart were first IP-ed using JNK isoform specific antibodies. Using an ADP-Glo enzyme activity assay, we found that the activity of the JNK2 isoform was significantly increased, while JNK1 was unchanged in aged WT mice compared with that of young WT controls ( Figure 3A and B) . Next, we discovered that CaMKIId protein was remarkably elevated (by 60%) in aged WT mice compared with that of young mice ( Figure 3C ). JNK2 inhibition in aged WT mice reversed this age-associated up-regulation of CaMKIId proteins ( Figure 3C , far right). Taken together, the results from both aged humans and aged mice strongly suggest that JNK2 is required for upregulated CaMKIId protein expression in the aged heart.
Activation of JNK2 leads to increased CaMKIId protein expression in cultured HL-1 myocytes
To further measure the action of activated JNK2 on CaMKIId expression in myocytes, we took advantage of a well-characterized mouse atrial HL-1 myocyte line. HL-1 myocytes have been shown to express cardiac genes and proteins, including ion channels and mature isoforms of sarcomeric contractile proteins normally found in adult myocytes. 6, 27, [30] [31] [32] Co-expression of the JNK activator MKK7D and JNK2 in HL-1 myocytes led to increased CaMKIId expression (by 40%), whereas co-expression of MKK7D and JNK1 did not ( Figure 4A) . Similarly, stimulation of cells with anisomycin (a JNK activator) 6 for 24 h led to a marked increase in the CaMKIId protein level (by 60% compared with the control, Figure 4B ). We acknowledge that anisomycin may not be a JNK specific activator. To exclude potential off-target anisomycin actions, we have included the use of specific JNK2 inhibition either by a JNK2 inhibitor or overexpressed inactivated JNK2 dominant negative proteins to help delineate the contribution of JNK2 in anisomycin-induced CaMKII expression in myocytes. When cultured HL-1 myocytes were pretreated with a JNK2-specific inhibitor JNK2I-IX, this anisomycin-induced up-regulation of CaMKIId was completely abolished ( Figure 4B , far right lanes/bar). Moreover, we infected HL-1 myocytes with adenovirus expressing either inactivated dominant negative JNK1 (JNK1dn) or dominant negative JNK2 (JNK2dn) followed by anisomycin treatment for 24 h. We found that inactive JNK2dn expression attenuated this anisomycin-induced upregulation of CaMKIId, while overexpression of JNK1dn had no such preventive effect on CaMKIId proteins ( Figure 4C and D). Collectively, these results demonstrate a JNK2 isoform-specific action in enhanced CaMKIId protein expression.
Up-regulated CaMKIId mRNA in the aged human atrium and JNK-activated cultured HL-1 myocytes
Using quantitative real-time PCR, we found that CaMKIId mRNA was significantly increased in the human atrium, and it was positively correlated with age ( Figure 5A ). This was consistent with the results we observed for CaMKIId protein expression in the human atrium ( Figure 1B) . Similarly, in HL-1 myocytes, CaMKIId mRNA was remarkably elevated by both JNK activator anisomycin (about 100% increase, Figure 5B ) and the upstream activating kinase MKK7D (about 70% increase, Figure 5C ). Altogether, these results indicate that JNK upregulates CaMKIId mRNA expression.
JNK enhances the binding of JNK downstream transcription factor c-jun to the CaMKIId gene promoter
JNKs mediate multiple cellular processes through phosphorylation of their downstream targets, particularly the transcription factor activator protein-1 (AP-1) complex. [33] [34] [35] Thus, we analysed the phosphorylation status of JNK downstream AP-1 transcription factors, c-jun and ATF2, using phospho-specific antibodies. As shown in Figure 6A and B, 
phosphorylated c-jun was significantly increased in aged mouse hearts, while phosphorylated ATF2 remained unchanged compared with that of young controls. Similarly, phospho-c-jun was also increased in anisomycin-treated HL-1 myocytes compared with sham controls, while fractionation of HL-1 myocytes showed that anisomycin remarkably increased c-jun-P proteins in the nuclei ( Figure 6C) . It is conceivable that activated c-jun triggers CaMKIId transcription. However, which transcription factors regulate CaMKIId gene expression has not been defined to date. Whether or not c-jun and ATF2 bind to and regulate the CaMKII gene promoter remains completely unknown.
To test this hypothesis, we first performed silico analysis of CaMKIId gene with the JASPAR programme (http://jaspar.genereg.net) and identified a highly matched c-jun and ATF2 binding consensus 1210 bp upstream of the mouse CaMKIId transcription start site. Importantly, this consensus is also conserved in the human CaMKIId gene. To examine the binding of c-jun and ATF2 to the CaMKIId gene, we employed a unique XChIP assay using c-jun or ATF2 protein immunoprecipitation and quantitative real-time qPCR with primers encompassing the identified putative AP-1 binding site of the CaMKIId promoter. We discovered that both c-jun and ATF2 bind to the CaMKIId gene. Interestingly, we found that the binding of c-jun was markedly enhanced when myocytes were treated with JNK activator anisomycin for 24 h (Figure 6D ), while ATF2 was unchanged. Moreover, JNK specific inhibitor SP600125 significantly reduced binding of c-jun proteins to the CaMKIId promoter ( Figure 6D, far right) . These results indicate that activation of JNK increases phosphorylation of the downstream target c-jun and thereby preferentially promotes the binding of c-jun to the CaMKIId gene promoter. 
Specific action of JNK2 in CaMKIId up-regulation via c-jun-enhanced CaMKIId promoter activity
To address whether enhanced binding of c-jun to the CaMKIId gene leads to an increase in CaMKIId transcription, JNK action on CaMKIId promoter activity was assessed. We amplified a 1.2 kb-long fragment from the mouse CaMKIId gene containing our newly identified binding sites as described above and inserted it into a luciferase reporter vector ( Figure 7A) . The activity of firefly luciferase downstream of the CaMKIId promoter was significantly augmented by anisomycin treatment for 24 h ( Figure 7B, left bar) . Further, we mutated the putative AP-1 binding consensus (by replacing -716 T/-715 G to A/C) on the CaMKIId promoter. This AP-1 binding consensus mutation not only eliminated anisomycinaugmented activity of the CaMKIId promoter, but also markedly reduced the baseline CaMKIId promoter activity ( Figure 7B) . These results suggest a critical regulatory role of AP-1 in CaMKIId expression.
Just as we have demonstrated that JNK2 is crucial in the up-regulation of CaMKIId expression, we have also assessed the effect of JNK2 siRNA knockdown on CaMKIId promoter activity. We found that JNK2 depletion attenuated anisomycin-induced enhancement of CaMKIId promoter activity ( Figure 7C Figure 7D) . Taken together, these results revealed for the first time that the binding of c-jun to the CaMKIId gene is functional and the JNK2 isoform directly up-regulates the transcriptional activity of CaMKIId via a JNK-enhanced c-jun binding to the CaMKIId promoter ( Figure 7E ).
Discussion
We have discovered a previously unrecognized molecular mechanism of JNK2 isoform-specific action in up-regulating the expression of a proarrhythmic molecule CaMKIId in the aged atrium. We have also revealed a novel underlying molecular mechanism where activated JNK2 increases CaMKIId transcription activity via direct binding of the JNK downstream target c-jun to the CaMKIId promoter.
Role of JNK in CaMKIId up-regulation and enhanced AF propensity in aging
JNK, originally identified as a stress protein kinase, is activated in response to a variety of extrinsic and intrinsic stresses. 2, 36 During the aging process, cardiomyocytes undergo various cellular changes such as enhanced oxidative stress as well as accumulating other chemical or biophysical stresses in the heart. 37, 38 Although JNK may be activated with increasing age as the stresses accumulate, 6,39 our current and previous results suggest that activated atrial JNK is a consistent feature of aged atrium among different species (humans, rabbits, and mice). 6, 7 Aging is an important risk factor for AF, the most common arrhythmia, affecting millions worldwide. [8] [9] [10] Our laboratory recently discovered a causal link between activated JNK and AF development in the aged heart. 6, 7 Although the underlying mechanisms of age-associated AF propensity remain incompletely understood, our current studies reveal that stress kinase JNK2 plays a pivotal role in regulating the expression of CaMKIId, a pro-arrhythmic molecule. [15] [16] [17] [18] [19] The JNK contribution to the CaMKII/RyR remodelling in fibrillating atria warrants further investigation. But, this investigation may be confounded by the complexity of AF causes, duration of AF progression, age and many other factors. This makes it difficult to distinguish whether CaMKII-dependent Ca 2þ mishandling in the fibrillating atrium is a preexisting arrthythmogenic remodelling or the consequence of AF-begets-AF. Our current results from aged human and animal atria, in hearts with no history of AF or CVD history, provide evidence of age-related CaMKIId up-regulation and enhanced atrial arrhythmogenicity by activated JNK, predisposing the heart to the onset of AF. Recent studies indicate that alterations of CaMKIId-dependent phosphorylation of Ca 2þ triggered Ca 2þ release RyR channels are present in the atria of chronic AF patients. Moreover, results in several animal models show that altered SR Ca 2þ handling proteins contribute to enhanced diastolic SR Ca 2þ leak and AF development. 13, 14, 40 Many studies have
shown LV CaMKII expression and activity are significantly increased in patients with advanced heart failure as well as in animal models of cardiac hypertrophy and heart failure. [41] [42] [43] We and others have previously demonstrated that enhanced activation of ventricular CaMKIId is critically involved in phosphorylation of Ca 2þ handling proteins, which results in sensitization of RyR channels and consequent triggered activities and arrhythmia. 15, [43] [44] [45] [46] [47] [48] [49] Thus, development of drugs to target CaMKIId activity has been proposed as a potential anti-arrhythmic intervention. 20 ,21 CaMKIId expression could be an alternative approach to targeting the CaMKIId molecule. Our discovery of the isoform-specific action of JNK2 in CaMKIId expression has shed new light on the possibility of inhibiting isoform specific JNK2 activity as a novel therapeutic intervention to prevent or treat cardiac arrhythmias.
Novel findings of isoform specific action of JNK2 in CaMKIId expression
CaMKIId is critical in regulating a large number of cellular substrates including ion channels, pumps, transporters and transcription factors. 22 Yet, how the expression of CaMKIId itself is controlled remains surprisingly understudied. Here, we uncovered the underlying molecular mechanism to explain how JNK2 up-regulates CaMKIId gene expression. JNK1 and JNK2 are the two predominant isoforms expressed in the heart. 2, 6 JNK1 has been shown to be critical in preserving cardiac function, preventing nerve degeneration, and promoting apoptosis in hearts with in vitro ischemia-reperfusion. 28 Conversely, the functions of JNK2 in the heart have not been well defined to date. Here, we have identified JNK2 as a key factor in up-regulated CaMKIId expression. While the concordantly activated JNK and upregulated CaMKIId were found in both aged human atria and animal models (with either JNK naturally activated by aging in WT mice or activated genetically in MKK7D young mice), the rescue effect of JNK2 ablation on JNK-induced CaMKII upregulation from JNK2 inhibitor-treated aged mice and JNK activator anisomycin-treated myocytes, demonstrate a key regulatory role of the JNK2 isoform in CaMKIId protein expression. It is known that JNK regulates its downstream gene expression through active or inactive AP-1, which is composed of JNK-regulated transcription factors (TFs) including c-jun and ATF2. 7, 33 The AP-1 complex regulates its target gene expression by binding the AP-1 consensus site(s) in the promoter region of target genes, or by dissociating from the promoter region to activate or suppress the specific gene expression. 7, 33 To date, transcription factors that regulate CaMKIId gene expression remain completely unknown. We discovered, for the first time, that JNK downstream transcription factor c-jun and ATF2 both bind to the CaMKIId gene and play a critical role in regulating CaMKII expression. This is supported by our results of suppressed CaMKII promoter activity when the AP-1 binding consensus sites were mutated. Another novel finding here is that JNK increases the binding of c-jun, but not ATF2, to the CaMKIId promoter. Further, JNK inhibition alleviated this enhanced c-jun binding, and JNK2 or c-jun specific siRNA knockdown rescued JNK-driven c-jun action on CaMKIId promoter activity. These intriguing rescue results of JNK2 inhibition in CaMKIId expression suggest that manipulating JNK2 activity could be an appealing antiarrhythmia therapeutic approach. 
Conclusions and potential implications of the results
Age-associated AF vulnerability is clinically significant. Our focus was to begin defining the role of JNK in CaMKII expression in normal aged atria that have no history of AF or CVD. We have demonstrated a causative action of activated JNK2 in up-regulating the pro-arrhythmic molecule CaMKIId in the aged atrium. Given that our current studies have revealed JNK2 to be a key regulator of the pro-arrhythmic CaMKIId, our new findings are clinically important and shed light on the possibility of modulating isoform specific activity of JNK as a novel therapeutic intervention approach to prevent or treat AF, with even broader applications for other cardiac arrhythmias in the elderly and heart failure patients. Clearly, JNK-driven CaMKII expression in aged and failing ventricles as well as possible atria-ventricle chamber differences deserve further studies. Also, CaMKII was reported to contribute to cardiac remodelling. 50 Although the absence of atrial structural remodelling in normal aging hearts has not been observed, 6, 51 the relationship between JNK, CaMKII, and structural remodelling also warrants further investigation in future studies. JNK2-specific action in CaMKIId gene expression
